Streetbeat News

CMMB

Chemomab Therapeutics Ltd.

https://www.chemomab.com

Industry

Biotechnology

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Open

1.69

Mkt cap

30M

Volume

122K

High

1.69

P/E Ratio

-1.68

52-wk high

2.55

Low

1.58

Div yield

N/A

52-wk low

0.45

Chemomab's CM-101 shows promising clinical activity across multiple biomarkers and potential to modify disease in Primary Sclerosing Cholangitis, as presented at AASLD The Liver Meeting® 2024.

Portfolio Pulse from

November 19, 2024 | 12:15 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Gainers included Gritstone Bio, Hoth Therapeutics, Lipella Pharmaceuticals, Enveric Biosciences, Oncternal Therapeutics, and Chemomab Therapeutics. Losers included Virpax Pharmaceuticals, Burning Rock Biotech, Mainz Biomed, CareDx, Inventiva, and Novo Integrated Sciences.

Portfolio Pulse from Benzinga Insights

October 15, 2024 | 12:08 pm

Recursion Pharmaceuticals shares fell 11.6% after announcing Phase 2 data for a treatment for Cerebral Cavernous Malformation. Nikola shares also dipped 10.4%. Meanwhile, Sify Technologies surged 103% after achieving a significant certification, and SPAR Group rose 65% following an acquisition agreement.

Portfolio Pulse from Avi Kapoor

September 03, 2024 | 5:41 pm

Chemomab has announced that its liquidity resources of $12.8 million as of June 30, 2024, combined with an additional $10 million raised in July 2024, will support its operations until early 2026.